NCT06050317View on ClinicalTrials.gov

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 18, 2023

Primary Completion Date

August 18, 2025

Study Completion Date

August 18, 2026

Conditions
Pancreas Cancer
Interventions
DRUG

Sintilimab Plus mFFN or NALIRIFOX and Radiation

Sintilimab Plus mFFN or NALIRIFOX and Radiation

Trial Locations (1)

0531

RECRUITING

Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan

All Listed Sponsors
lead

Shandong Cancer Hospital and Institute

OTHER